Janssen Bows Out as Contender for Horizon Therapeutics Buyout

And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday.

Last week, Horizon confirmed it was engaged in “highly preliminary discussions” with three separate pharma giants – Amgen, Sanofi and Janssen – regarding a potential acquisition. The Wall Street Journal first reported the news.